Clinical trials
Renal Insufficiency, Chronic trials in Hong Kong
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 6 |
| Not yet recruiting | 4 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Hong Kong | 7 |
| Chinese University of Hong Kong | 3 |
| Novartis Pharmaceuticals | 3 |
| Alexion Pharmaceuticals, Inc. | 2 |
| Bayer | 2 |
| Boehringer Ingelheim | 2 |
| The Hong Kong Polytechnic University | 2 |
| Amgen | 1 |
| AstraZeneca | 1 |
| Elaine Chow | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 32 |
| Glomerulonephritis, IGA | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Glomerulonephritis | 3 |
| Hypertension | 3 |
| Kidney Failure, Chronic | 3 |
| Anemia | 2 |
| Diabetic Nephropathies | 2 |
| Hyperparathyroidism, Secondary | 2 |
| Kidney Diseases | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.